A sacubitril-valsartan therapy regimen was associated with greater reductions in NT-proBNP concentrations in patients with HFrEF compared with enalapril. Patients with HFrEF who were hospitalized ...

Potential adverse effects include hypotension, hyperkalemia, angioedema, and risk of renal injury, they added in the interview, ... Cost-Benefit Ratio of Sacubitril/Valsartan 9.

Sacubitril/valsartan did not significantly reduce the rate of CV death, HF hospitalization or outpatient HF requiring treatment following acute MI compared with ramipril, according to results of ...

Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II–receptor blockers (ARBs ...

A Danish study finds that recalled blood pressure and heart failure drugs containing tainted valsartan were not linked with a significant increase in overall cancer risk, in the short term. More ...

Sacubitril/valsartan was associated with reduced natriuretic peptides and lower risk for CV death and HF hospitalization across the spectrum of ejection fraction, particularly in those with EF ...

These products — with the active ingredient valsartan, a generic drug used to treat high blood pressure — may contain N-nitrosodimethylamine (NDMA), a possible human carcinogen.